Pub-2022

Articles

Title
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia
Response and survival predictors in a cohort of 319 patients with Waldenstr€om macroglobulinemia treated with ibrutinib monotherapy
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
Long-term follow-up of ibrutinib monotherapy in treatmentnaive patients with Waldenstrom macroglobulinemia
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Venetoclax in Previously Treated Waldenstrom Macroglobulinemia
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study